Enhanced activation of the NF-κB pathway, together with increased numbers of monocytes and M2 macrophages, suggest that MAPK inhibition may lead to changes in the tumor microenvironment and contribute to therapy resistance together with alterations within the tumor itself [247]. Here, NFKB1 is linked to neoplasm.